Ann: Trading Halt, page-28

Via AFR:
Heart health group Anteris Technologies is seeking to restock its funding warchest with a $24 million placement via Evolution Capital on Tuesday.The group’s shares went into a trading halt as the stockbroker started drumming up bids at $24 a share, which was a 0.2 per cent discount to the last close.The DurAVR technology has been designed to last longer and restore blood flow for aortic stenosis patients. AFRThe deal was structured as a placement of 1 million new shares, with ability to increase the deal by up to $6 million.Each new share had an option attached, on a one-for-one basis and exercisable at $29 within two years.The deal launched with $15 million in cornerstone commitments, the term sheet sent to fund managers at lunchtime on Tuesday said.
Funds raised would be used for clinical development of its DurAVR THV product, and working capital. DurAVR is a prosthetic aortic valve, which the company has been trialling on humans since 2021.The raising comes only days after Anteris announced a non-binding capital facility with US-based investor Yorkville Advisors Global LP, worth up to $50 million. The facility was subject to due diligence, internal approvals and entry into a binding agreement.Anteris had a $334 million market capitalisation prior to Tuesday’s placement.